

### Amendments to the Claims

1. (Previously Presented) A method of preventing the formation of inhibitory antibodies to Factor IX delivered to a mammal by way of an adeno-associated viral vector, wherein said mammal has a genetic defect which can result in generation of inhibitory antibodies to Factor IX, said method comprising intravenously or intraperitoneally administering to said mammal cyclophosphamide prior to or simultaneously with said adeno-associated viral vector delivery before formation of said inhibitory antibodies, the delivered Factor IX being from the same species as said mammal.

2. (Previously Presented) The method of claim 1, wherein said mammal and gene are human.

3-23. (Cancelled)

24. (Previously Presented) The method of claim 1, wherein said mammal has no detectable endogenous expression of the delivered Factor IX.

25-27. (Cancelled)

28. (Previously Presented) The method of claim 1, wherein said cyclophosphamide is administered concomitantly with said adeno-associated viral vector.

29-42. (Cancelled)

43. (Currently amended) The method of claim 1, wherein Factor IX production in said mammal induces formation of said inhibitory antibodies which are optionally ~~is~~ determined by Bethesda titers.

44. (Previously presented) The method of claim 1, wherein said mammal has hemophilia B.